Price (90d)
$586.67Signal Score (90d)
150Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $4.30B | $1.06B | $13.17 |
| 2024 | $3.90B | $887.87M | $10.77 |
| 2023 | $3.66B | $845.04M | $10.17 |
| 2022 | $3.37B | $679.09M | $8.12 |
| 2021 | $3.22B | $744.85M | $8.74 |
Social Signal Score
Earnings
Mon, Nov 2(in 3 months)
Consensus estimate $3.71 per share
Typical surprise +8.3% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 4$4.27 vs $3.94beat
- Tue, May 5$3.47 vs $3.41beat
- Mon, Feb 2$3.08 vs $2.93beat
- Mon, Nov 3$3.40 vs $3.14beat
- Mon, Aug 4$3.63 vs $3.28beat
- Thu, May 1$2.96 vs $2.85beat
Estimates and results for IDXX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
Project earnings forward and see what return today's price implies.
Seeded from IDXX's reported EPS growth of 10.8% a year over 4 years.
- EPS in 5 years
- $22.09
- Implied price
- $1,127
- Return from $550.96
- 15.4% a year
To earn 15.0% a year on these assumptions you'd need to buy at $560.09 — today's price is already 1.6% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 35 | 43 | 51 | 59 | 67 |
|---|---|---|---|---|---|
| 0.8% | -2.6% | 1.4% | 5.0% | 8.1% | 10.9% |
| 5.8% | 2.2% | 6.5% | 10.2% | 13.4% | 16.4% |
| 10.8% | 7.0% | 11.5% | 15.4% | 18.8% | 21.9% |
| 15.8% | 11.8% | 16.5% | 20.6% | 24.2% | 27.3% |
| 20.8% | 16.7% | 21.6% | 25.8% | 29.5% | 32.8% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Mentions (4)
- News (RSS)seekingalpha·22h ago·Neutral
IDEXX Laboratories, Inc. (IDXX) Analyst/Investor Day - Slideshow
View source ↗ - Newsmarketbeat.com·1d ago·Neutral
IDEXX Laboratories Targets $45B Pet Diagnostics Opportunity With AI, Cancer Tests IDEXX Laboratories NASDAQ: IDXX outlined an innovation-led growth strategy at its 2026 Investor Day, highlighting a $45 billion global companion-animal testing opportunity, expanded commercial investments and a pipeline of diagnostic, software and artificial-intelligence offerings intended to increase testing utilization in veterinary practices.
View source ↗ - Newszacks.com·3d ago·Positive
Here's Why Idexx Laboratories (IDXX) is a Strong Growth Stock The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
View source ↗ - Newsseekingalpha.com·7d ago·Positive
IDEXX Laboratories: Worth The Premium IDEXX Laboratories remains a buy, supported by a durable moat, strong recurring revenue, and a long-term international growth runway. Recent Q2 2026 results showed 9% organic revenue growth, EPS guidance raised to $14.69–14.94, and robust expansion of diagnostic offerings. Installed base growth for core machines is moderating in the US but remains early-stage internationally, underpinning multi-decade expansion potential.
View source ↗